Coagulation and Haemorrhagic Disorders
Coagulation disorders present as abnormal bleeding that may be acquired or inherited. Inherited disorders include haemophilia and von Willebrand disease (VWD) that arise from deficiencies in clotting factor VIII or IX, and platelet dysfunction, respectively.
Featured Learning Zones
Fibrinogen is an essential coagulation factor in the blood clotting cascade. The importance for fibrinogen in normal haemostasis is highlighted in patients of inherited fibrinogen deficiencies who display coagulopathies such as excessive bleeding and thrombolytic events.
Acquired coagulation disorders can result from vitamin K deficiency, liver disease, disseminated intravascular coagulation (DIC) and high levels of circulating anticoagulants (including oral vitamin K antagonists and non-vitamin K oral anticoagulants prescribed to patients with diseases such as atrial fibrillation, heart failure, valvular heart disease and venous thromboembolism). Deficiencies in factors that regulate the blood clotting process acquired during bleeding (for example, during trauma, postpartum haemorrhage and cardiac surgery) may also lead to coagulation complications, including factor I (fibrinogen), II (prothrombin), V, VII, X, or XII deficiencies.
Diagnosis of a coagulation disorder varies according to the patient situation. Common tests include prothrombin time (PT), activated partial prothromboplastin time (aPTT) and thrombin time (TT) as well as other targeted diagnostic tests including the Clauss assay, and point-of-care viscoelastic devices such as rotational thromboelastometry (ROTEM) and thromboelastography (TEG) that assess blood clotting ability and fibrinogen function. Treatment varies according to the cause of bleeding and may include factor replenishment (for example, factor concentrates, fresh frozen plasma, cryoprecipitate) and oral anticoagulation reversal.
To find out more on the management of coagulation and haemorrhagic disorders, please visit our learning zones on fibrinogen deficiency and oral anticoagulation reversal.
Related news and insights
Swedish Orphan Biovitrum AB (publ) (Sobi) and Apellis Pharmaceuticals Inc. announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally.
Spectrum Pharmaceuticals announced that an inspection of the Hanmi Bioplant in South Korea is required before the FDA can approve the company’s Biologics License Application (BLA) for Rolontis.
Additional positive results were announced from Part A of a pivotal Phase III trial evaluating the investigational use of Dupixent (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE).
The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging...
Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and...